Zovaglutide: Molecular Structure

Molecular Structure#

Zovaglutide (ZT-002) is a peptide-based GLP-1 receptor agonist with an innovative structural modification that sets it apart from existing agents in the class. While the detailed amino acid sequence has not been publicly disclosed, the key structural feature -- a dual-fatty acid chain design -- has been described by QL Biopharm.

Dual Fatty Acid Chain Design#

The defining structural innovation of zovaglutide is the incorporation of two fatty acid chains, rather than the single chain used by semaglutide and other acylated GLP-1 RAs:

Semaglutide approach (single chain):

• One C18 fatty diacid connected via a linker to a GLP-1 analog backbone
• Provides strong albumin binding sufficient for weekly dosing
• Half-life of approximately 7 days

Zovaglutide approach (dual chain):

• Two fatty acid chains attached to the peptide backbone
• Significantly enhanced albumin binding affinity
• Half-life 2-4 fold longer than semaglutide across multiple species
• Supports once-monthly (Q4W) dosing

Mechanism of Half-Life Extension#

The fatty acid chains act as albumin-binding moieties. When zovaglutide binds to serum albumin (which has a half-life of approximately 19-21 days in humans), the drug is protected from proteolytic degradation and renal clearance. The dual-chain design increases the albumin binding affinity beyond what a single chain achieves, resulting in tighter and more sustained albumin association.

Chemical Properties#

Pharmacokinetics#

The pharmacokinetic profile of zovaglutide is its primary competitive advantage:

• Half-life: 2-4 fold longer than semaglutide (estimated ~14-28 days), enabling monthly dosing
• Albumin binding: Enhanced affinity due to dual fatty acid chains
• Absorption: Subcutaneous depot with slow, sustained release into systemic circulation
• Steady-state: Achieved with monthly dosing; plasma levels maintained throughout the dosing interval

Comparison with Other GLP-1 RAs#

Stability#

Detailed stability data for zovaglutide have not been publicly disclosed. The dual-fatty acid modification, in addition to extending half-life, may also confer improved stability to the peptide backbone through steric shielding from proteases when bound to albumin.

Molecular Context#

Zovaglutide belongs to the Metabolic category of research peptides. The molecular properties of Zovaglutide determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.

Structural Overview#

Zovaglutide is characterized as: Zovaglutide is a GLP-1 receptor agonist peptide featuring a dual-fatty acid chain modification that enhances albumin binding affinity, extending its half-life 2-4 fold compared to semaglutide. This enables once-monthly subcutaneous dosing while maintaining sustained GLP-1 receptor activation..

Amino Acid Sequence Details#

The amino acid sequence of Zovaglutide is: Proprietary GLP-1 analog with dual fatty acid chain modification (not publicly disclosed). This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.

Pharmacokinetic Profile#

Half-Life: 2-4x longer than semaglutide (supporting once-monthly dosing)

The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.

Related Reading#

• Zovaglutide overview and research guide
• Peptides similar to Zovaglutide
• Zovaglutide research evidence